Berylson Capital Partners’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-24,550
Closed -$2.02M 23
2024
Q2
$2.02M Buy
24,550
+8,800
+56% +$951K 5.15% 7
2024
Q1
$2.28M Hold
15,750
4.57% 6
2023
Q4
$1.45M Sell
15,750
-3,750
-19% -$381K 2.7% 16
2023
Q3
$3.22M Buy
19,500
+4,700
+32% +$611K 8.24% 2
2023
Q2
$935K Buy
+14,800
New +$897K 2.64% 17
2022
Q4
Sell
-28,800
Closed -$2.71M 22
2022
Q3
$2.71M Buy
28,800
+18,420
+177% +$2.62M 4.47% 11
2022
Q2
$2.32M Buy
10,380
+4,110
+66% +$1.38M 6.26% 6
2022
Q1
$3.45M Sell
6,270
-1,380
-18% -$834K 4.04% 9
2021
Q4
$5.06M Sell
7,650
-11,330
-60% -$8.66M 5.57% 7
2021
Q3
$15.9M Buy
18,980
+2,310
+14% +$2.34M 7.37% 3
2021
Q2
$21.2M Sell
16,670
-1,770
-10% -$2M 4.69% 2
2021
Q1
$20.2M Buy
18,440
+2,350
+15% +$3.1M 4.92% 4
2020
Q4
$23M Sell
16,090
-1,860
-10% -$1.98M 3.93% 4
2020
Q3
$12.7M Buy
+17,950
New +$13M 4.43% 5
2020
Q2
Sell
-6,548
Closed -$2.29M 30
2020
Q1
$2.29M Buy
+6,548
New +$4.64M 6.17% 6

Other funds holding CDLX

Berylson Capital Partners's CDLX Position: Q3 2024 in Review

Berylson Capital Partners sold out of Cardlytics (CDLX) in Q3 2024, closing a stake of 24,550 shares — an estimated $2.02M sold.

Berylson Capital Partners first reported a position in CDLX in Q1 2020 and held it in 15 quarters. The position peaked at $23M in Q4 2020. 111 funds tracked by Wall St. Rank hold CDLX as of Q3 2024.

  • Berylson Capital Partners reported no remaining Cardlytics position as of Q3 2024 after selling out during the quarter.
  • Berylson Capital Partners sold 24,550 Cardlytics shares in Q3 2024, an estimated $2.02M.
  • Berylson Capital Partners first reported a position in Cardlytics in Q1 2020 and held it in 15 quarters.
  • Berylson Capital Partners's Cardlytics position peaked at $23M in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Cardlytics as of Q3 2024.

Based on Berylson Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.